JW0104 + C2403

JW0104 + C2403 is an investigational combination drug regimen under development by JW Pharmaceutical. While data on C2403 remains limited, JW0104 is a small molecule drug in late-stage clinical trials (Phase 3) for cardiovascular and metabolic indications such as hypertension and dyslipidemia. The combination is being studied for safety and pharmacokinetic profile in healthy volunteers, suggesting it is at the early clinical evaluation stage as a fixed-dose combination. There is currently no detailed published information regarding the precise mechanism of action or chemical structure for either JW0104 or C2403; however, JW0104 is primarily developed for cardiovascular disorders, indicating likely activity on targets relevant to hypertension or lipid regulation[2][4].